P504 Effectiveness and adverse events of azathioprine in inflammatory bowel disease: 9-year follow-up study

Guerra, Iván; Algaba, Alicia; Serrano, A. Lesmes; Aulló, Carolina; Alcalde, Daniel; Lucas, Matthias; Bonillo, Daniel; Zapatero, A.; Bermejo, Fernando

doi:10.1016/s1873-9946(14)60624-3

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a retrospective analysis, where AZA-associated toxicities were evaluated among 198 patients with IBD, the most common AEs were hepatotoxicity (8%), and the rates of GI intolerance and AP were found to be 3% and 2.5%, respectively. 26 Among our patients, the most common AEs were GI intolerance (3.7%), AP (3.3%), and hematologic toxicities (3.1%), although not mentioned here in detail.…”

Section: Discussionmentioning

confidence: 69%

Frequency, Predisposing Factors, and Clinical Outcome of Azathioprine-Induced Pancreatitis Among Patients With Inflammatory Bowel Disease

et al. 2021

View full text Add to dashboard Cite

The aim of the study was to identify the frequency of azathioprine-induced acute pancreatitis (AZA-AP) and related factors.Methods: Seven hundred eighty-seven inflammatory bowel disease (IBD) patients on AZA therapy were retrospectively analyzed. Azathioprineinduced AP was diagnosed with positive imaging and/or an at least 3fold increased amylase level, in presence of typical abdominal pain. The AZA-AP group was compared with patients on AZA therapy with no history of pancreatitis and 4 numerical adjacent cases with the same diagnosis were selected (group B).Results: Fifty-four patients developed gastrointestinal symptoms (6.9%); however, only half of them (26 of 54) had pancreatitis, except 1, all within the first 2 months under AZA. When the AZA-AP group was compared with group B, only budesonide usage and active smoking were significantly more common in group A (46.2% vs 25%, P = 0.034, and 77% vs 51%, P = 0.017, respectively). Active smoking was the only independent risk factor for AZA-AP development (odds ratio, 3.208 [95% confidence interval, 1.192-8.632]). Conclusions:All IBD patients developed AZA-AP nearly all within the first 2 months. Azathioprine intolerance may be a hidden diagnosis in at least half of the patients with AZA-AP symptoms. All smoker IBD patients should be monitored closely for AZA-AP development.

show abstract

Section: Discussionmentioning

confidence: 69%

Frequency, Predisposing Factors, and Clinical Outcome of Azathioprine-Induced Pancreatitis Among Patients With Inflammatory Bowel Disease

et al. 2021

View full text Add to dashboard Cite

show abstract

Side effects from the use of azathioprine in Crohn's disease: A systematic review

2016

View full text Add to dashboard Cite

Introduction: Crohn's disease is a chronic, relapsing and inflammatory condition. Azathioprine (AZA) is an immunosuppressive drug used for maintenance of the disease remission. However, the side effects this drug causes to patients, makes it questionable, as to its safety, for health. Purpose: To determine the type and severity of side effects caused by AZA treatment in Crohn's disease. Materials and methods: Through systematic review of literature, 85 studies were found, 10 of which were selected. The selection criteria were: a) articles, which were primary studies, reviews or meta-analyzes, b) available in full text, c) written in English and d) finally articles, referring to humans. Results: Studies show that AZA, is drug of choice, for treating Crohn's disease. However, side effects from its use are numerous and increasing in severity. According to the survey results, people who used this drug, developed at some point in their treatment, side effects such as hepatotoxicity, myelotoxicity, acute pancreatitis (p<0.001), gastrointestinal intolerance, general hardship, blood disorders, fever wave, itching and arthralgia. Conclusions: Recommendations from these studies show that side effects immerge from almost all systems in the patient's body, but it is not proven if all of them have to do exclusively with the drug or the disease’s nature. As AZA holds a prominent role in disease’s treatment, the use of more thorough controls is recommended for simultaneous treatment of side effects.

show abstract

P504 Effectiveness and adverse events of azathioprine in inflammatory bowel disease: 9-year follow-up study

Cited by 2 publications

References 0 publications

Frequency, Predisposing Factors, and Clinical Outcome of Azathioprine-Induced Pancreatitis Among Patients With Inflammatory Bowel Disease

Frequency, Predisposing Factors, and Clinical Outcome of Azathioprine-Induced Pancreatitis Among Patients With Inflammatory Bowel Disease

Side effects from the use of azathioprine in Crohn's disease: A systematic review

Contact Info

Product

Resources

About